Purpose: To assess the connection between the prevalence of asthenopia and the use of electronic devices in Jazan, Saudi Arabia, during the COVID-19 pandemic. Patients and Methods: Asthenopia prevalence and its connection to electronic screens during the COVID-19 pandemic were evaluated in an analytical, cross-sectional investigation among the Jazan population. The sample population included 784 participants. Due to the COVID-19 pandemic, a pre-tested, organized, and self-administered questionnaire was used as the study method. Social media invitations were used to contact the sample group. Results: Of the 784 participants, 587 (74.96%) had asthenopia symptoms after using digital devices at the end of the day. A total of 56.30% used digital gadgets for > 6 hours each day, whereas 55.36% spent < 2 hours per day reading papers or books or writing. Daily usage of digital gadgets did not significantly differ from asthenopia (p=0.46), as well as reading papers, books, or writing and asthenopia (p=0.098). A total of 45.92% of the study population maintained digital devices/books at a distance < 25 cm, which was significantly associated with symptoms of asthenopia (p=0.048). Furthermore, 90.10% of the sample population used laptops, cellphones, and iPads before going to bed or after turning off lights. A total of 63.52% preferred using devices while lying in bed. There was no positive link between asthenopia symptoms and cellphone usage at bedtime or after turning off lights (p=0.028). Conclusion: Digital technology is used by people of all ages for a wide range of daily activities, including education, employment, business, and recreation. We concluded that this group had a high prevalence of asthenopia, especially during the COVID-19 pandemic. The high frequency of asthenopia emphasizes the significance of conducting public awareness campaigns concerning asthenopia symptoms and prevention methods.

Background: Computer vision syndrome (CVS) can be described as ocular-related symptoms that result from prolonged exposure and use of computers, smartphones, tablets, and other devices with digital displays. The main objective of this study was to investigate the prevalence of CVS among school-age children, the associated signs, risk factors, and the association between the disease before and during the COVID-19 pandemic in the Jazan region of Saudi Arabia. Methods: The study employed a descriptive cross-sectional research design. The targeted population was school-going children aged 6 to 18 in the Jazan region in the Southwest of Saudi Arabia. A sample of 440 participants was selected to represent the population under study. Data were collected using self-administered questionnaires. Sociodemographic characteristics were recorded, such as age, gender, education level, parents’ education, occupation, frequency, and intensity of eye symptoms if present. Results: Most of the participants were adolescents between 16 and 18 and at a high-school education level. According to the total symptoms score, the CVS prevalence was 35.4%. Prevalence of CVS significantly affects age, gender, and school level (p < 0.05 for all). A similar significant association was reported between the symptoms experienced before and during COVID-19 and the CVS (p < 0.05). Conclusion: A total of 407 adolescents aged 16–18 responded to the questionnaire (response rate of 92.5%; 407 out of 440). The study estimated the prevalence of CVS among school-going children in Jazan to be low. The main signs associated with CVS included headache, tearing, itchiness, blurred vision, eye redness, eye pain, and dryness. The attitude of children toward their health condition during the COVID-19 pandemic and the prevalence of CVS have a significant relationship.

Retinal vessel segmentation is critical in detecting retinal blood vessels for a variety of eye disorders, and a consistent computerized method is required for automatic eye disorder screening. Many methods of retinal blood vessel segmentation are implemented, but these methods only yielded accuracy and lack of good sensitivity due to the coherence of retinal blood vessel segmentation. Another main factor of low sensitivity is the proper technique to handle the low-varying contrast problem. In this study, we proposed a five-step technique for assessing the impact of retinal blood vessel coherence on retinal blood vessel segmentation. The proposed technique for retinal blood vessels involved four steps and is known as the preprocessing module. These four stages of the pre-processing module handle the retinal image process in the first stage, uneven illumination and noise issues using morphological operations in the second stage, and image conversion to grayscale using principal component analysis (PCA) in the third step. The fourth step is the main step of contributing to the coherence of retinal blood vessels using anisotropic diffusion filtering and testing their different schemes and get a better coherent image on the optimized anisotropic diffusion filtering. The last step included double thresholds with morphological image reconstruction techniques to produce a segmented image of the vessel. The performances of the proposed method are validated on the publicly available database named DRIVE and STARE. Sensitivity values of 0.811 and 0.821 on STARE and DRIVE respectively meet and surpass other existing methods, and comparable accuracy values of 0.961 and 0.954 on STARE and DRIVE databases to existing methods. This proposed new method for retinal blood vessel segmentations can help medical experts diagnose eye disease and recommend treatment in a timely manner.

Healthcare-associated conjunctivitis (HAC) has been associated with serious ophthalmological complications in neonates, including blindness. This three-year retrospective, descriptive study was conducted between 2019 and 2021 to determine the most common bacteria associated with neonatal HAC at a tertiary-care hospital in Saudi Arabia. The inclusion criteria were defined based on the centers for disease control and prevention (CDC) guidelines for the diagnosis of neonatal HAC. When HAC was clinically suspected, conjunctival swabs were obtained from neonates and sent to the microbiology lab following standard protocols. A univariate analysis was conducted on the included samples. A total of 79 cases met our inclusion criteria and were retrospectively studied. A descriptive analysis showed that Pseudomonas aeruginosa was the leading cause of HAC, with 25% (20 cases), followed by Escherichia coli and Klebsiella pneumonia (11.5% for each). About 9% of the analyzed cases were positive for Staphylococcus aureus. Orogastric feeding was the most commonly (94%) associated factor with HAC, followed by respiratory distress syndrome (RDS) and preterm birth, which were found in 70% and 64% of the cases, respectively. To conclude, HAC is an alarming healthcare problem, and bacteria, including Gram-negative bacteria, are common causes. Thus, physician awareness, effective communication with microbiologists, and the implementation of infection control recommendations, including hand hygiene, could minimize this problem and avoid the serious complications of HAC.

Background/Objectives: Brolucizumab is a humanized single-chain antibody fragment with a molecular weight of approximately 26 kilodaltons (scFv, ~26 kDa) targeting all VEGF-A isoforms. Intravitreal brolucizumab (6 mg) is FDA-approved for neovascular age-related macular degeneration (nAMD) (2019) and diabetic macular edema (DME) (2022). We systematically review the literature on brolucizumab for nAMD and DME, focusing on efficacy, safety, pharmacokinetics, real-world outcomes, and cost-effectiveness in adult and pediatric patients. Methods: Our method involves a comprehensive literature search of PubMed, Embase, Scopus, Cochrane, and related databases (through late 2024) using terms including “brolucizumab,” “Beovu,” “neovascular AMD,” “diabetic macular edema,” “safety,” “pharmacokinetics,” and “pediatric.” High-quality clinical trials, meta-analyses, regulatory documents, and real-world studies were prioritized. Results: In pivotal Phase III trials (HAWK/HARRIER for nAMD), brolucizumab 6 mg demonstrated non-inferior visual acuity (VA) gains to aflibercept, with >50% of eyes maintained on 12-week dosing and greater retinal fluid reduction. In DME trials (KESTREL/KITE), brolucizumab was similarly non-inferior to aflibercept for VA and showed superior anatomic drying, with 33–48% of eyes maintained on ≥12-week intervals. However, brolucizumab use has been associated with intraocular inflammation (IOI), retinal vasculitis, and vascular occlusion: clinical trials and post hoc analyses reported higher rates of these events than comparator agents. Real-world cohorts found IOI in ~4–10% of treated eyes, often occurring early (within 3 months) after initiation. Conclusions: In conclusion, Brolucizumab is an effective anti-VEGF option for nAMD and DME, providing durable anatomic control with fewer injections. Non-inferior vision outcomes and superior fluid resolution have been demonstrated. However, it carries a distinct risk of IOI and occlusive vasculitis, necessitating careful patient selection, dosing, and monitoring.

Background and Objectives: The COVID-19 pandemic affects various populations worldwide. The discovery of vaccinations was necessary for the prevention and elimination of the disease. Despite the high importance of these vaccinations, they may cause some complications, such as ocular complications. This study aims to draw attention to the possible complications of the vaccination and highlight its importance. Materials and Methods: Systematic review of the literature from January 2021 to January 2023. A total of 20 published articles were included and reported cases of ocular complications in patients who received COVID-19 vaccines. Results: A total of 243 patients with verified ocular complications following the COVID-19 vaccination were included, ranging in age from 18 to 84 years. The most common ocular complications reported in the current study were ocular inflammatory complications, which represented 47.3%, followed by optic neuritis (24.3%). Retinal artery occlusion, retinal vein occlusion, acute macular neuroretinopathy, and paracentral acute middle maculopathy represented 10.7%. Herpetic ocular infections and herpetic eye disease (14%). Nearly half (42%) of the patients with ocular problems received the Pfizer-BioNTech vaccination. Conclusions: Despite the high importance of the COVID-19 vaccination, it was found that it is associated with the occurrence of some ocular complications. Future projects should come with more extensive prospective studies to further elucidate the underlying mechanisms and risk factors associated with ocular complications following COVID-19 vaccination, thereby enhancing our understanding and guiding appropriate management strategies.